TXG Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -23.58% compared to 10x Genomics's net margin of 3.36%. 10x Genomics's return on equity of -24.99% beat Astrana Health's return on equity of 12.67%.

10x Genomics has a consensus price target of $20.29, signalling upside risk potential of 37.72%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 92.71%. Given that Astrana Health has higher upside potential than 10x Genomics, analysts believe Astrana Health is more attractive than 10x Genomics.

10x Genomics has a beta of 1.839, which suggesting that the stock is 83.931% more volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.

10x Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10x Genomics pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.

10x Genomics quarterly revenues are $151.7M, which are smaller than Astrana Health quarterly revenues of $478.7M. 10x Genomics's net income of -$35.8M is lower than Astrana Health's net income of $16.1M. Notably, 10x Genomics's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10x Genomics is 2.80x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -23.58% compared to 10x Genomics's net margin of 8.15%. 10x Genomics's return on equity of -24.99% beat Cryo-Cell International's return on equity of --.

10x Genomics has a consensus price target of $20.29, signalling upside risk potential of 37.72%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 16.43%. Given that 10x Genomics has higher upside potential than Cryo-Cell International, analysts believe 10x Genomics is more attractive than Cryo-Cell International.

10x Genomics has a beta of 1.839, which suggesting that the stock is 83.931% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.

10x Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.23% to investors and pays a quarterly dividend of $0.25 per share. 10x Genomics pays -- of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

10x Genomics quarterly revenues are $151.7M, which are larger than Cryo-Cell International quarterly revenues of $8M. 10x Genomics's net income of -$35.8M is lower than Cryo-Cell International's net income of $655.8K. Notably, 10x Genomics's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10x Genomics is 2.80x versus 2.00x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -23.58% compared to 10x Genomics's net margin of 3.06%. 10x Genomics's return on equity of -24.99% beat Omnicell's return on equity of -1.47%.

10x Genomics has a consensus price target of $20.29, signalling upside risk potential of 37.72%. On the other hand Omnicell has an analysts' consensus of -- which suggests that it could grow by 27.13%. Given that 10x Genomics has higher upside potential than Omnicell, analysts believe 10x Genomics is more attractive than Omnicell.

10x Genomics has a beta of 1.839, which suggesting that the stock is 83.931% more volatile than S&P 500. In comparison Omnicell has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.577%.

10x Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10x Genomics pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

10x Genomics quarterly revenues are $151.7M, which are smaller than Omnicell quarterly revenues of $282.4M. 10x Genomics's net income of -$35.8M is lower than Omnicell's net income of $8.6M. Notably, 10x Genomics's price-to-earnings ratio is -- while Omnicell's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10x Genomics is 2.80x versus 1.92x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -23.58% compared to 10x Genomics's net margin of -12.84%. 10x Genomics's return on equity of -24.99% beat P3 Health Partners's return on equity of -26.35%.

10x Genomics has a consensus price target of $20.29, signalling upside risk potential of 37.72%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 222.33%. Given that P3 Health Partners has higher upside potential than 10x Genomics, analysts believe P3 Health Partners is more attractive than 10x Genomics.

10x Genomics has a beta of 1.839, which suggesting that the stock is 83.931% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

10x Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10x Genomics pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

10x Genomics quarterly revenues are $151.7M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. 10x Genomics's net income of -$35.8M is higher than P3 Health Partners's net income of -$46.5M. Notably, 10x Genomics's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10x Genomics is 2.80x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.